KEYNOTE-355 showed a significant (27 percent) reduction in the risk of death for patients whose tumors were highly positive for PD-L1, as measured by a Combined Positive Score (CPS) of 10 or higher. Previous reports have confirmed that patients with newly diagnosed locally advanced or metastatic TNBC and high tumor levels of PD-L1 experienced improved progression-free and overall survival when treated with pembrolizumab plus chemotherapy compared to those receiving chemotherapy alone. KEYNOTE-355 is a phase III study of chemotherapy with and without the addition of pembrolizumab in advanced TNBC. Javier Cortes of the International Breast Cancer Center in Madrid reported that a baseline level of PD-L1-positivity is a marker of response to pembrolizumab in patients with advanced TNBC tumors. Presenting final overall survival analyses of Keynote 355, Dr. Pembrolizumab targets the PD-1/PD-L1 pathway, which is utilized by tumor cells to evade the immune system. The utility of adding pembrolizumab (Keytruda®)-an immunotherapy agent that targets the PD-L1 protein-to a chemotherapy regimen for treating early-stage and high-risk TNBC or advanced TNBC was the subject of two major sessions at SABCS that detailed the results of KEYNOTE-355 ( NCT02819518) and KEYNOTE 522 ( NCT03036488). Immunotherapy benefits seen in early and advanced TNBC, and PD-L1 protein levels reported to be a key indicator of response in advanced disease Developments in Triple-Negative Breast Cancer (TNBC) ![]() Click these links to jump ahead to each section below. Here, we report the highlights from this year’s conference presentations on triple-negative, hormone receptor (HR)–positive/HER2-negative, and HER2-positive breast cancer. Findings at this year’s symposium showed that we’re making progress to expand and improve treatment options and tackle some of breast cancer’s biggest challenges, including brain metastases and triple-negative disease. ![]() The 2021 San Antonio Breast Cancer Symposium (SABCS) heralded promising clinical trial results for breast cancer patients-particularly for those living with metastatic disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |